Galderma has updated the FDA on its Biologics License Application (BLA) for relabotulinum toxinA, signaling continued advancement toward potential approval. Relabotulinum is a recombinant botulinum toxin designed to offer a differentiated potency and diffusion profile compared to Botox (onabotulinumtoxinA) and Revance's DaxibotulinumtoxinA (Daxxify).
The competitive toxin market is consolidating: AbbVie's Botox dominates via Allergan Aesthetics and the Allē loyalty program; Revance holds a smaller but growing share with Daxxify's longer duration (6 months vs. Botox's 3–4 months); and Evolus' Jeuveau captures price-sensitive segments. Galderma's entry, if approved, introduces a third major player and could trigger pricing pressure across the category—similar to what occurred when Jeuveau launched in 2019.